EP1003896A1 - Hüllprotein-modifizierter baculovirus-vektor für die gentherapie - Google Patents
Hüllprotein-modifizierter baculovirus-vektor für die gentherapieInfo
- Publication number
- EP1003896A1 EP1003896A1 EP98947386A EP98947386A EP1003896A1 EP 1003896 A1 EP1003896 A1 EP 1003896A1 EP 98947386 A EP98947386 A EP 98947386A EP 98947386 A EP98947386 A EP 98947386A EP 1003896 A1 EP1003896 A1 EP 1003896A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vector
- vector according
- virus
- sequence
- baculovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the invention relates to a coat protein-modified baculovirus vector for gene therapy; Areas of application are medicine, biotechnology and genetic engineering.
- baculovirus vector that can transfer therapeutic genes highly specifically and effectively into liver cells.
- Baculoviruses belong to a family of large DNA viruses, the host spectrum of which is naturally restricted to arthropods. Your genome (80kbp-200kpb) is packaged in flexible nucleocapsids that allow the insertion of large amounts of foreign DNA.
- the decisive prerequisite for bacuioviral gene transfer in mammalian cells is the insertion of an expression cassette that is functional in mammalian cells. This created an important prerequisite for the therapy of genetic diseases of the liver.
- the aim of this invention is the construction of a Baculoviru ⁇ vector which, by modifying the virus envelope, escapes inactivation by serum components and transfers therapeutic genes highly specifically and effectively in liver cells in vivo.
- the therapeutic DNA sequence for the vector according to the invention is the cDNA of a gene which is defective in the disease to be treated, i.e. missing or changed by mutation. It is also possible to use part of a genomic sequence which spans a mutation in the target gene and can homologously recombine with it.
- the first line serves as strong viral promoters, preferably the very early promoter of the Cyto arcadeieviru ⁇ (CMV). Cell-specific protorotors are also suitable.
- the establishment sequence has the task of stabilizing the vector in the cell without integration into the genome. It is used particularly in cases where long-term expression is required.
- Preferred establishment sequences according to the invention are viral core establishment sequences, such as the Ep ⁇ tein-Barr virus, or autonomous replication sequences from the mammalian genome.
- the new vectors are produced in the following essential steps:
- a novel vector for gene transfer is created which offers considerable advantages over the virus vectors developed so far (retroviruses, adenoviruses and unmodified baculoviruses). These include the stability in blood and serum, the liver specificity or free variation of the cell targeting, the almost unlimited possibility of incorporating foreign DNA, the infection of cells that are unable to divide, the lack of cytotoxicity and the simple generation of high-titre recombinant viruses.
- the envelope protein-modified Baculoviru ⁇ vectors enable a desired gene to be introduced into the affected organ of a patient and to optimally design his way to the functional site.
- the application of the vector can be local or systematic. A essential prerequisite for successful therapy of genetic and malignant diseases of humans is thereby created. The invention will be explained in more detail below by means of exemplary embodiments.
- Insect cells manufactured. 10 ul of the viruses were with 90 ul
- a sequence for an N-terminally modified baculovirus envelope protein (gp64) is cloned in a known manner in a recombination vector under the control of a baculoviral promoter.
- the modification is achieved by inserting the DNA sequence for amino acids 1-320 of the complement protection protein "decay accelerating factor (DAF)" between the signal sequence and the sequence of the baculovirus protein gp64 at the DNA level.
- DAF decay accelerating factor
- This construct is either cloned into the recombination vector, which contains the therapeutic DNA sequences together with the promoter, or is stably integrated into the virus packaging cell.
- the modified coat protein is inserted into the envelope of the baculovirus vector and thereby mediates:
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1997135593 DE19735593C2 (de) | 1997-08-15 | 1997-08-15 | Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie |
DE19735593 | 1997-08-15 | ||
PCT/DE1998/002255 WO1999009193A1 (de) | 1997-08-15 | 1998-08-05 | Hüllprotein-modifizierter baculovirus-vektor für die gentherapie |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1003896A1 true EP1003896A1 (de) | 2000-05-31 |
Family
ID=7839201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98947386A Withdrawn EP1003896A1 (de) | 1997-08-15 | 1998-08-05 | Hüllprotein-modifizierter baculovirus-vektor für die gentherapie |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1003896A1 (de) |
JP (1) | JP2003530064A (de) |
CA (1) | CA2300362A1 (de) |
DE (1) | DE19735593C2 (de) |
ES (1) | ES2150894T1 (de) |
WO (1) | WO1999009193A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6183993B1 (en) * | 1996-09-11 | 2001-02-06 | The General Hospital Corporation | Complement-resistant non-mammalian DNA viruses and uses thereof |
GB0012997D0 (en) * | 2000-05-26 | 2000-07-19 | Eurogene Limited | Gene delivery |
US6607912B2 (en) | 2000-08-11 | 2003-08-19 | Boyce Thompson Institute For Plant Research, Inc. | GP64-null baculoviruses pseudotyped with heterologous envelope proteins |
CA2440342A1 (en) | 2001-03-12 | 2002-09-19 | Ark Therapeutics Ltd. | Avidin-pseudotyped viral vectors and their use |
EP1392837A2 (de) * | 2001-05-29 | 2004-03-03 | Ark Therapeutics Limited | Gentransfer mittels eines baculoviralen vektors |
GB0119852D0 (en) | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
US6863884B2 (en) | 2002-05-01 | 2005-03-08 | Cell Genesys, Inc. | Pseudotyped retroviral vectors |
US7416890B2 (en) | 2002-09-25 | 2008-08-26 | Osaka Industrial Promotion Organization | Baculovirus vector, method of producing thereof and method of gene transfer |
EP1548119A4 (de) * | 2002-09-25 | 2006-08-02 | Osaka Ind Promotion Org | Baculovirusvektor, verfahren zur konstruktion des baculovirusvektors und gentransfer-verfahren |
WO2006069220A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Modified human growth hormone |
JP4896745B2 (ja) | 2004-02-02 | 2012-03-14 | アンブレツクス・インコーポレイテツド | 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用 |
JP2008503217A (ja) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
GB0425739D0 (en) * | 2004-11-23 | 2004-12-22 | Procure Therapeutics Ltd | Humanised baculovirus 2 |
MX2007007587A (es) | 2004-12-22 | 2007-12-11 | Ambrx Inc | Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural. |
US7638491B2 (en) | 2004-12-22 | 2009-12-29 | Ambrx, Inc. | Therapies using non-natural amino acids and polypeptides |
KR20070100299A (ko) | 2004-12-22 | 2007-10-10 | 암브룩스, 인코포레이티드 | 재조합 인간 성장 호르몬의 발현 및 정제 방법 |
WO2006068802A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF |
WO2006133089A2 (en) | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
JP2009520949A (ja) | 2005-11-16 | 2009-05-28 | アンブルックス,インコーポレイテッド | 非天然アミノ酸を含んでいる組成物および方法 |
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
AU2007292892B9 (en) | 2006-09-08 | 2013-02-28 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
AU2007292903B2 (en) | 2006-09-08 | 2012-03-29 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
CA2682147C (en) | 2007-03-30 | 2017-08-08 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
NZ580686A (en) | 2007-05-02 | 2012-11-30 | Ambrx Inc | Modified interferon beta polypeptides and their uses |
CN101918026B (zh) | 2007-11-20 | 2016-03-02 | Ambrx公司 | 经修饰胰岛素多肽和其用途 |
CN101939443B (zh) | 2008-02-08 | 2014-01-29 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
ES2654387T3 (es) | 2008-07-23 | 2018-02-13 | Ambrx, Inc. | Polipéptidos G-CSF bovinos modificados y sus usos |
PT2342223T (pt) | 2008-09-26 | 2017-07-07 | Lilly Co Eli | Polipéptidos de eritropoetina animal modificados e suas utilizações |
MX343802B (es) | 2008-09-26 | 2016-11-23 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales. |
EA201290541A1 (ru) | 2009-12-21 | 2013-05-30 | Амбркс, Инк. | Модифицированные бычьи соматотропиновые полипептиды и их применение |
CA2784800A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
MA34521B1 (fr) | 2010-08-17 | 2013-09-02 | Ambrx Inc | Polypeptides de relaxine modifiés et leurs utilisations |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
JPWO2016059911A1 (ja) * | 2014-10-17 | 2017-07-27 | 国立大学法人金沢大学 | マラリアワクチン |
LT3412302T (lt) | 2014-10-24 | 2021-07-26 | Bristol-Myers Squibb Company | Modifikuoti fgf-21 polipeptidai ir jų panaudojimai |
SG11201907209QA (en) | 2017-02-08 | 2019-09-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4407859C1 (de) * | 1994-03-04 | 1995-03-02 | Max Planck Gesellschaft | Vektor für die leberspezifische Gentherapie |
WO1996009074A1 (en) * | 1994-09-23 | 1996-03-28 | The General Hospital Corporation | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
US5750383A (en) * | 1996-05-14 | 1998-05-12 | Boyce Thompson Institute For Plant Research, Inc. | Baculovirus cloning system |
-
1997
- 1997-08-15 DE DE1997135593 patent/DE19735593C2/de not_active Expired - Fee Related
-
1998
- 1998-08-05 EP EP98947386A patent/EP1003896A1/de not_active Withdrawn
- 1998-08-05 WO PCT/DE1998/002255 patent/WO1999009193A1/de not_active Application Discontinuation
- 1998-08-05 CA CA002300362A patent/CA2300362A1/en not_active Abandoned
- 1998-08-05 ES ES98947386T patent/ES2150894T1/es active Pending
- 1998-08-05 JP JP2000509856A patent/JP2003530064A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9909193A1 * |
Also Published As
Publication number | Publication date |
---|---|
DE19735593A1 (de) | 1999-02-18 |
CA2300362A1 (en) | 1999-02-25 |
DE19735593C2 (de) | 1999-08-26 |
WO1999009193A1 (de) | 1999-02-25 |
ES2150894T1 (es) | 2000-12-16 |
JP2003530064A (ja) | 2003-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19735593C2 (de) | Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie | |
DE69829471T2 (de) | Auf lentivirus basierende gentransfer-vektoren | |
DE69333471T2 (de) | Erzielbare vektorenpartikel | |
DE69518910T3 (de) | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle | |
DE60034478T2 (de) | Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber | |
DE69635172T2 (de) | Rekombinanter MVA Virus und seine Verwendung | |
DE69634300T2 (de) | Gentherapie mit hilfe von schaf-adenoviralen vektoren | |
DE69834936T2 (de) | Vektor zur gewebespezifischen replikation und expression | |
WO1995029993A1 (en) | Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line | |
DE69936577T2 (de) | Lentivirale Verpackungszellen | |
EP0961830A1 (de) | Expressionvektoren und methoden zur in vivo expression von therapeutischen polypeptiden | |
MX9709549A (es) | Adenovirus recombinantes, su uso para preparar aav, linea celular complementaria y composiciones farmaceuticas que los contienen. | |
CA2224114A1 (en) | Synthetic mammalian chromosome and methods for construction | |
EP0723460A1 (de) | Gentherapie für das nervensystems | |
KR100484883B1 (ko) | 바이러스성입자를생산하는캡슐화세포 | |
DE69725882T2 (de) | Adenovirus e4 proteine für induktion von zelltod | |
DE4407859C1 (de) | Vektor für die leberspezifische Gentherapie | |
DE69627644T2 (de) | Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie | |
EP0839205A1 (de) | Leberspezifischer adenovirus-expressionsvektor | |
EP0716711A1 (de) | Vektor für leber-gentherapie | |
DE19807265C2 (de) | Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz | |
EP0889968A2 (de) | Psa positiv regulierende sequenzen und verwendung davon | |
EP1544305A1 (de) | Adapter zum Ankoppeln einer an einer Zelloberfläche anzukoppelnden Substanz | |
EP1000167B2 (de) | Herstellung humaner mutierter proteine in humanen zellen mittels homologer rekombination | |
WO1996003517A1 (de) | Verfahren zur herstellung von viren und viralen vektoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000208 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT CH DE ES FR GB IE IT LI NL SE |
|
GBC | Gb: translation of claims filed (gb section 78(7)/1977) | ||
EL | Fr: translation of claims filed | ||
TCNL | Nl: translation of patent claims filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: BA2A Ref document number: 2150894 Country of ref document: ES Kind code of ref document: T1 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DEVELOGEN AKTIENGESELLSCHAFT FUER ENTWICKLUNGSBIOL |
|
IECL | Ie: translation for ep claims filed | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040229 |